ALUMIS INC. - COMMON S

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

14 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

13 ноя 2024 16:05:48 Источник Nasdaq GlobeNewswire

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

04 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

27 сен 2024 09:00:00 Источник Nasdaq GlobeNewswire

Alumis to Participate in Upcoming September Investor Conferences

03 сен 2024 16:29:30 Источник Nasdaq GlobeNewswire

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

13 авг 2024 16:05:27 Источник Nasdaq GlobeNewswire

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

29 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire